<p>2025 年 4 月 30 日- 下午 1:46</p>
<p>加利福尼亞州帕洛阿爾託，2025 年 4 月 30 日（環球新聞通訊社）-- Scilex Holding Company（納斯達克代碼：SCLX，“Scilex” 或 “公司”），是一家創新的創收公司，專注於收購、開發和商業化非阿片類疼痛管理產品，以治療急性和慢性疼痛以及神經退行性和心代謝疾病，今天宣佈已收到納斯達克證券市場有限責任公司的通知，確認公司已重新符合納斯達克上市規則 5550(a)(2) 下的最低收盤競價要求。為了重新符合要求，公司必須在至少連續十個交易日內維持每股最低收盤競價為 1.00 美元。該要求於 2025 年 4 月 30 日得到滿足。</p>
<p>公司的普通股和公開認股權證將繼續在納斯達克資本市場交易，交易代碼分別為 “SCLX” 和 “SCLXW”。</p>
<p>有關 Scilex Holding Company 的更多信息，請訪問 www.scilexholding.com</p>
<p>有關 Semnur Pharmaceuticals, Inc.的更多信息，請訪問 www.semnurpharma.com</p>
<p>有關 ZTlido®的更多信息，包括完整的處方信息，請訪問 www.ztlido.com。</p>
<p>有關 ELYXYB®的更多信息，包括完整的處方信息，請訪問 www.elyxyb.com。</p>
<p>有關 Gloperba®的更多信息，包括完整的處方信息，請訪問 www.gloperba.com。</p>
<p>https://www.facebook.com/scilex.pharm</p>
<p>https://www.linkedin.com/company/scilex-holding-company/</p>
<p>info@scilexholding.com</p>
<p><strong>關於 Scilex Holding Company</strong></p>
<p>Scilex Holding Company 是一家創新的創收公司，專注於收購、開發和商業化非阿片類疼痛管理產品，以治療急性和慢性疼痛以及神經退行性和心代謝疾病。Scilex 針對具有高未滿足需求和大市場機會的適應症，致力於為急性和慢性疼痛患者提供非阿片類療法，並致力於改善患者的治療效果。Scilex 的商業產品包括：(i) ZTlido®（利多卡因局部系統）1.8%，一種由美國食品藥品監督管理局（“FDA”）批准的處方利多卡因局部產品，用於緩解與帶狀皰疹後神經痛相關的神經性疼痛；(ii) ELYXYB®，一種潛在的一線治療藥物，是唯一獲得 FDA 批准的即用型口服溶液，用於急性治療成人偏頭痛，無論是否伴有先兆；(iii) Gloperba®，首個也是唯一的液體口服版本的抗痛風藥物秋水仙鹼，適用於成人痛風發作的預防。</p>
<p>此外，Scilex 還有三個產品候選者：(i) SP-102（10 毫克，磷酸氟氯噻噸粘稠凝膠）（“SEMDEXA” 或 “SP-102”），一種新型的粘稠凝膠配方，廣泛用於硬膜外注射以治療腰骶根性疼痛或坐骨神經痛，Scilex 已完成第三階段研究，並於 2017 年獲得 FDA 的快速通道資格；(ii) SP-103（利多卡因局部系統）5.4%（“SP-103”），一種下一代三倍強度的 ZTlido 配方，用於急性疼痛的治療，Scilex 最近已完成急性下背痛的第二階段試驗。SP-103 已獲得 FDA 在下背痛方面的快速通道資格；(iii) SP-104（4.5 毫克，低劑量納曲酮鹽酸鹽緩釋膠囊）（“SP-104”），一種新型低劑量緩釋納曲酮鹽酸鹽，正在開發用於治療纖維肌痛。</p>
<p>Scilex Holding Company 總部位於加利福尼亞州帕洛阿爾託。</p>
<p><strong>前瞻性聲明</strong></p>
<p>本新聞稿及在本新聞稿中討論的事項的任何陳述均包含與 Scilex 及其子公司相關的前瞻性聲明，依據 1995 年《私人證券訴訟改革法》第 21E 條的安全港條款，可能面臨風險和不確定性，這可能導致實際結果與預測結果存在重大差異。前瞻性聲明包括關於 Scilex 潛在開發和商業化肥胖、神經退行性、心代謝疾病治療的聲明。</p>
<p>可能導致 Scilex 實際結果與我們前瞻性聲明中表達的結果存在重大不利差異的風險和不確定性包括但不限於：Scilex 保持符合納斯達克持續上市要求的能力，以及維持公司證券在納斯達克的上市；Scilex 開發和商業化肥胖症、神經退行性疾病、心代謝疾病治療的能力；與交易市場的不確定性相關的風險，以及是否會為 Scilex 的普通股建立市場；一般經濟、政治和商業環境；與 COVID-19（及其他類似干擾）相關的風險；Scilex 開發的潛在產品候選者可能無法按預期時間表推進臨牀開發或獲得所需的監管批准的風險；與 Scilex 產品候選者的監管路徑不確定性相關的風險；Scilex 可能無法成功營銷或獲得市場對其產品候選者的接受的風險；Scilex 的產品候選者可能對患者沒有益處或未能成功商業化的風險；Scilex 可能高估了目標患者羣體的規模、他們嘗試新療法的意願以及醫生開處方這些療法的意願的風險；SP-102、SP-103 或 SP-104 的試驗和研究結果可能不成功或未能反映積極結果的風險；SP-102（SEMDEXA™）、SP-103 或 SP-104 的臨牀和研究者發起的試驗的先前結果可能無法複製的風險；監管和知識產權風險；以及不時指出的其他風險和不確定性，以及在 Scilex 最近向證券交易委員會提交的定期報告中描述的其他風險，包括 Scilex 截至 2024 年 12 月 31 日的年度報告（Form 10-K）和隨後提交的季度報告（Form 10-Q），包括這些文件中列出的風險因素。投資者被提醒不要過度依賴這些前瞻性聲明，這些聲明僅在本發佈之日有效，Scilex 沒有義務更新本新聞稿中的任何前瞻性聲明，除非法律要求。</p>
<p><strong>聯繫方式：</strong></p>
<p>投資者和媒體</p>
<p>Scilex Holding Company</p>
<p>960 San Antonio Road</p>
<p>帕洛阿爾託，加利福尼亞州 94303</p>
<p>辦公室： (650) 516-4310</p>
<p>電子郵件： investorrelations@scilexholding.com</p>
<p>網站： www.scilexholding.com</p>
<p>SEMDEXA™ (SP-102) 是 Semnur Pharmaceuticals, Inc.的商標，Semnur Pharmaceuticals, Inc.是 Scilex Holding Company 的全資子公司。計劃進行 FDA 的專有名稱審查。</p>
<p>ZTlido® 是 Scilex Pharmaceuticals Inc.的註冊商標，Scilex Pharmaceuticals Inc.是 Scilex Holding Company 的全資子公司。</p>
<p>Gloperba® 是 Scilex Holding Company 擁有的註冊商標的獨佔、可轉讓使用許可的主題。</p>
<p>ELYXYB® 是 Scilex Holding Company 擁有的註冊商標。</p>
<p>所有其他商標均為其各自所有者的財產。</p>
<p>© 2025 Scilex Holding Company 保留所有權利。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RRME1qQTFNaU0yT1RFME1qVXhJekl5TlRRM01qYz0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RRME1qQTFNaU0yT1RFME1qVXhJekl5TlRRM01qYz0"/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/YzIyNGUzY2MtODc1My00NDg0LTg2ODUtMDRjYTU3YjZiNDZlLTEyNjYyNzYtMjAyNS0wNC0zMC1lbg==/tiny/Scilex-Holding-Company.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/YzIyNGUzY2MtODc1My00NDg0LTg2ODUtMDRjYTU3YjZiNDZlLTEyNjYyNzYtMjAyNS0wNC0zMC1lbg==/tiny/Scilex-Holding-Company.png"/></p>

SCLX

<p>Scilex Holding Company 已經重新符合納斯達克的最低出價要求，截至 2025 年 4 月 30 日，連續十個交易日的收盤出價保持在每股 1.00 美元。該公司的普通股和公開認股權證將繼續在納斯達克資本市場交易，交易代碼為 "SCLX" 和 "SCLXW"。Scilex 專注於非阿片類疼痛管理產品，並在其產品組合中擁有多個獲得 FDA 批准的治療方案和產品候選者</p>

<p>04/30/2025 - 01:46 PM</p>
<div class="lb-trans"><p>2025 年 4 月 30 日- 下午 1:46</p>
</div><p>PALO ALTO, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease, today announced that it has received notification from The Nasdaq Stock Market LLC that the Company has regained compliance with the minimum closing bid price requirement under Nasdaq Listing Rule 5550(a)(2). To regain compliance, the Company was required to maintain a minimum closing bid price of $1.00 per share for at least ten consecutive trading days. This requirement was met on April 30, 2025.</p>
<div class="lb-trans"><p>加利福尼亞州帕洛阿爾託，2025 年 4 月 30 日（環球新聞通訊社）-- Scilex Holding Company（納斯達克代碼：SCLX，“Scilex” 或 “公司”），是一家創新的創收公司，專注於收購、開發和商業化非阿片類疼痛管理產品，以治療急性和慢性疼痛以及神經退行性和心代謝疾病，今天宣佈已收到納斯達克證券市場有限責任公司的通知，確認公司已重新符合納斯達克上市規則 5550(a)(2) 下的最低收盤競價要求。為了重新符合要求，公司必須在至少連續十個交易日內維持每股最低收盤競價為 1.00 美元。該要求於 2025 年 4 月 30 日得到滿足。</p>
</div><p>The Company’s common stock and public warrants will continue to trade on the Nasdaq Capital Market under the symbols “SCLX” and “SCLXW”, respectively.</p>
<div class="lb-trans"><p>公司的普通股和公開認股權證將繼續在納斯達克資本市場交易，交易代碼分別為 “SCLX” 和 “SCLXW”。</p>
</div><p>For more information on Scilex Holding Company, refer to www.scilexholding.com</p>
<div class="lb-trans"><p>有關 Scilex Holding Company 的更多信息，請訪問 www.scilexholding.com</p>
</div><p>For more information on Semnur Pharmaceuticals, Inc., refer to www.semnurpharma.com</p>
<div class="lb-trans"><p>有關 Semnur Pharmaceuticals, Inc.的更多信息，請訪問 www.semnurpharma.com</p>
</div><p>For more information on ZTlido® including Full Prescribing Information, refer to www.ztlido.com.</p>
<div class="lb-trans"><p>有關 ZTlido®的更多信息，包括完整的處方信息，請訪問 www.ztlido.com。</p>
</div><p>For more information on ELYXYB®, including Full Prescribing Information, refer to www.elyxyb.com.</p>
<div class="lb-trans"><p>有關 ELYXYB®的更多信息，包括完整的處方信息，請訪問 www.elyxyb.com。</p>
</div><p>For more information on Gloperba®, including Full Prescribing Information, refer to www.gloperba.com.</p>
<div class="lb-trans"><p>有關 Gloperba®的更多信息，包括完整的處方信息，請訪問 www.gloperba.com。</p>
</div><p>https://www.facebook.com/scilex.pharm</p>
<div class="lb-trans"><p>https://www.facebook.com/scilex.pharm</p>
</div><p>https://www.linkedin.com/company/scilex-holding-company/</p>
<div class="lb-trans"><p>https://www.linkedin.com/company/scilex-holding-company/</p>
</div><p>info@scilexholding.com</p>
<div class="lb-trans"><p>info@scilexholding.com</p>
</div><p><strong>About Scilex Holding Company</strong></p>
<div class="lb-trans"><p><strong>關於 Scilex Holding Company</strong></p>
</div><p>Scilex Holding Company is an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease. Scilex targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and is dedicated to advancing and improving patient outcomes. Scilex’s commercial products include: (i) ZTlido® (lidocaine topical system) 1.8%, a prescription lidocaine topical product approved by the U.S. Food and Drug Administration (the “FDA”) for the relief of neuropathic pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain; (ii) ELYXYB®, a potential first-line treatment and the only FDA-approved, ready-to-use oral solution for the acute treatment of migraine, with or without aura, in adults; and (iii) Gloperba®, the first and only liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.</p>
<div class="lb-trans"><p>Scilex Holding Company 是一家創新的創收公司，專注於收購、開發和商業化非阿片類疼痛管理產品，以治療急性和慢性疼痛以及神經退行性和心代謝疾病。Scilex 針對具有高未滿足需求和大市場機會的適應症，致力於為急性和慢性疼痛患者提供非阿片類療法，並致力於改善患者的治療效果。Scilex 的商業產品包括：(i) ZTlido®（利多卡因局部系統）1.8%，一種由美國食品藥品監督管理局（“FDA”）批准的處方利多卡因局部產品，用於緩解與帶狀皰疹後神經痛相關的神經性疼痛；(ii) ELYXYB®，一種潛在的一線治療藥物，是唯一獲得 FDA 批准的即用型口服溶液，用於急性治療成人偏頭痛，無論是否伴有先兆；(iii) Gloperba®，首個也是唯一的液體口服版本的抗痛風藥物秋水仙鹼，適用於成人痛風發作的預防。</p>
</div><p>In addition, Scilex has three product candidates: (i) SP-102 (10 mg, dexamethasone sodium phosphate viscous gel) (“SEMDEXA” or “SP-102”), a novel, viscous gel formulation of a widely used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica, for which Scilex has completed a Phase 3 study and was granted Fast Track status from the FDA in 2017; (ii) SP-103 (lidocaine topical system) 5.4%, (“SP-103”), a next-generation, triple-strength formulation of ZTlido, for the treatment of acute pain and for which Scilex has recently completed a Phase 2 trial in acute low back pain. SP-103 has been granted Fast Track status from the FDA in low back pain; and (iii) SP-104 (4.5 mg, low-dose naltrexone hydrochloride delayed-release capsules) (“SP-104”), a novel low-dose delayed-release naltrexone hydrochloride being developed for the treatment of fibromyalgia.</p>
<div class="lb-trans"><p>此外，Scilex 還有三個產品候選者：(i) SP-102（10 毫克，磷酸氟氯噻噸粘稠凝膠）（“SEMDEXA” 或 “SP-102”），一種新型的粘稠凝膠配方，廣泛用於硬膜外注射以治療腰骶根性疼痛或坐骨神經痛，Scilex 已完成第三階段研究，並於 2017 年獲得 FDA 的快速通道資格；(ii) SP-103（利多卡因局部系統）5.4%（“SP-103”），一種下一代三倍強度的 ZTlido 配方，用於急性疼痛的治療，Scilex 最近已完成急性下背痛的第二階段試驗。SP-103 已獲得 FDA 在下背痛方面的快速通道資格；(iii) SP-104（4.5 毫克，低劑量納曲酮鹽酸鹽緩釋膠囊）（“SP-104”），一種新型低劑量緩釋納曲酮鹽酸鹽，正在開發用於治療纖維肌痛。</p>
</div><p>Scilex Holding Company is headquartered in Palo Alto, California.</p>
<div class="lb-trans"><p>Scilex Holding Company 總部位於加利福尼亞州帕洛阿爾託。</p>
</div><p><strong>Forward-Looking Statements</strong></p>
<div class="lb-trans"><p><strong>前瞻性聲明</strong></p>
</div><p>This press release and any statements made for and during any presentation or meeting concerning the matters discussed in this press release contain forward-looking statements related to Scilex and its subsidiaries under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995 and are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements include statements regarding Scilex’s potential development and commercialization of treatments for obesity, neurodegenerative, cardiometabolic disease.</p>
<div class="lb-trans"><p>本新聞稿及在本新聞稿中討論的事項的任何陳述均包含與 Scilex 及其子公司相關的前瞻性聲明，依據 1995 年《私人證券訴訟改革法》第 21E 條的安全港條款，可能面臨風險和不確定性，這可能導致實際結果與預測結果存在重大差異。前瞻性聲明包括關於 Scilex 潛在開發和商業化肥胖、神經退行性、心代謝疾病治療的聲明。</p>
</div><p>Risks and uncertainties that could cause Scilex’s actual results to differ materially and adversely from those expressed in our forward-looking statements, include, but are not limited to: Scilex’s ability to remain in compliance with the Nasdaq continued listing requirements and to maintain the listing of the Company’s securities thereon; Scilex’s ability to develop and commercialize treatments for obesity, neurodegenerative, cardiometabolic disease; risks associated with the unpredictability of trading markets and whether a market will be established for Scilex’s common stock; general economic, political and business conditions; risks related to COVID-19 (and other similar disruptions); the risk that the potential product candidates that Scilex develops may not progress through clinical development or receive required regulatory approvals within expected timelines or at all; risks relating to uncertainty regarding the regulatory pathway for Scilex’s product candidates; the risk that Scilex will be unable to successfully market or gain market acceptance of its product candidates; the risk that Scilex’s product candidates may not be beneficial to patients or successfully commercialized; the risk that Scilex has overestimated the size of the target patient population, their willingness to try new therapies and the willingness of physicians to prescribe these therapies; risks that the outcome of the trials and studies for SP-102, SP-103 or SP-104 may not be successful or reflect positive outcomes; risks that the prior results of the clinical and investigator-initiated trials of SP-102 (SEMDEXA™), SP-103 or SP-104 may not be replicated; regulatory and intellectual property risks; and other risks and uncertainties indicated from time to time and other risks described in Scilex’s most recent periodic reports filed with the Securities and Exchange Commission, including Scilex’s Annual Report on Form 10-K for the year ended December 31, 2024 and subsequent Quarterly Reports on Form 10-Q that the Company has filed or may file with the SEC, including the risk factors set forth in those filings. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release, and Scilex undertakes no obligation to update any forward-looking statement in this press release except as may be required by law.</p>
<div class="lb-trans"><p>可能導致 Scilex 實際結果與我們前瞻性聲明中表達的結果存在重大不利差異的風險和不確定性包括但不限於：Scilex 保持符合納斯達克持續上市要求的能力，以及維持公司證券在納斯達克的上市；Scilex 開發和商業化肥胖症、神經退行性疾病、心代謝疾病治療的能力；與交易市場的不確定性相關的風險，以及是否會為 Scilex 的普通股建立市場；一般經濟、政治和商業環境；與 COVID-19（及其他類似干擾）相關的風險；Scilex 開發的潛在產品候選者可能無法按預期時間表推進臨牀開發或獲得所需的監管批准的風險；與 Scilex 產品候選者的監管路徑不確定性相關的風險；Scilex 可能無法成功營銷或獲得市場對其產品候選者的接受的風險；Scilex 的產品候選者可能對患者沒有益處或未能成功商業化的風險；Scilex 可能高估了目標患者羣體的規模、他們嘗試新療法的意願以及醫生開處方這些療法的意願的風險；SP-102、SP-103 或 SP-104 的試驗和研究結果可能不成功或未能反映積極結果的風險；SP-102（SEMDEXA™）、SP-103 或 SP-104 的臨牀和研究者發起的試驗的先前結果可能無法複製的風險；監管和知識產權風險；以及不時指出的其他風險和不確定性，以及在 Scilex 最近向證券交易委員會提交的定期報告中描述的其他風險，包括 Scilex 截至 2024 年 12 月 31 日的年度報告（Form 10-K）和隨後提交的季度報告（Form 10-Q），包括這些文件中列出的風險因素。投資者被提醒不要過度依賴這些前瞻性聲明，這些聲明僅在本發佈之日有效，Scilex 沒有義務更新本新聞稿中的任何前瞻性聲明，除非法律要求。</p>
</div><p><strong>Contacts:</strong></p>
<div class="lb-trans"><p><strong>聯繫方式：</strong></p>
</div><p>Investors and Media</p>
<div class="lb-trans"><p>投資者和媒體</p>
</div><p>Scilex Holding Company</p>
<div class="lb-trans"><p>Scilex Holding Company</p>
</div><p>960 San Antonio Road</p>
<div class="lb-trans"><p>960 San Antonio Road</p>
</div><p>Palo Alto, CA 94303</p>
<div class="lb-trans"><p>帕洛阿爾託，加利福尼亞州 94303</p>
</div><p>Office: (650) 516-4310</p>
<div class="lb-trans"><p>辦公室： (650) 516-4310</p>
</div><p>Email: investorrelations@scilexholding.com</p>
<div class="lb-trans"><p>電子郵件： investorrelations@scilexholding.com</p>
</div><p>Website: www.scilexholding.com</p>
<div class="lb-trans"><p>網站： www.scilexholding.com</p>
</div><p>SEMDEXA™ (SP-102) is a trademark owned by Semnur Pharmaceuticals, Inc., a wholly-owned subsidiary of Scilex Holding Company. A proprietary name review by the FDA is planned.</p>
<div class="lb-trans"><p>SEMDEXA™ (SP-102) 是 Semnur Pharmaceuticals, Inc.的商標，Semnur Pharmaceuticals, Inc.是 Scilex Holding Company 的全資子公司。計劃進行 FDA 的專有名稱審查。</p>
</div><p>ZTlido® is a registered trademark owned by Scilex Pharmaceuticals Inc., a wholly-owned subsidiary of Scilex Holding Company.</p>
<div class="lb-trans"><p>ZTlido® 是 Scilex Pharmaceuticals Inc.的註冊商標，Scilex Pharmaceuticals Inc.是 Scilex Holding Company 的全資子公司。</p>
</div><p>Gloperba® is the subject of an exclusive, transferable license to use the registered trademark by Scilex Holding Company.</p>
<div class="lb-trans"><p>Gloperba® 是 Scilex Holding Company 擁有的註冊商標的獨佔、可轉讓使用許可的主題。</p>
</div><p>ELYXYB® is a registered trademark owned by Scilex Holding Company.</p>
<div class="lb-trans"><p>ELYXYB® 是 Scilex Holding Company 擁有的註冊商標。</p>
</div><p>All other trademarks are the property of their respective owners.</p>
<div class="lb-trans"><p>所有其他商標均為其各自所有者的財產。</p>
</div><p>© 2025 Scilex Holding Company All Rights Reserved.</p>
<div class="lb-trans"><p>© 2025 Scilex Holding Company 保留所有權利。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RRME1qQTFNaU0yT1RFME1qVXhJekl5TlRRM01qYz0" alt="" original-src="https://www.globenewswire.com/newsroom/ti?nf=OTQ0MjA1MiM2OTE0MjUxIzIyNTQ3Mjc="/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/YzIyNGUzY2MtODc1My00NDg0LTg2ODUtMDRjYTU3YjZiNDZlLTEyNjYyNzYtMjAyNS0wNC0zMC1lbg==/tiny/Scilex-Holding-Company.png" alt="" original-src="https://ml.globenewswire.com/media/YzIyNGUzY2MtODc1My00NDg0LTg2ODUtMDRjYTU3YjZiNDZlLTEyNjYyNzYtMjAyNS0wNC0zMC1lbg==/tiny/Scilex-Holding-Company.png"/></p>

Scilex 控股公司重新符合納斯達克最低出價規則 | SCLX 股票新聞